Recent Updates
Recently added Catalysts
CMPS Positive Sentiment

Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026

Key Takeaway: Compass Pathways plc will announce its financial results for the second quarter and first half of 2026 on August 5, 2026. The announcement highlights the company's commitment to providing new treatment options in mental health care. A conference call will follow the release, allowing for direct communication with management.
Price reaction · baseline $10.85 (2026-07-28 close) · hit pre-market · 2 other CMPS headline(s) in the window, move may be shared
day 0 close · peak
+0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Compass Pathways is focused on mental health care solutions.
  • The company is actively communicating its financial performance.
  • The upcoming conference call demonstrates transparency with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+247%
120-day peak, hindsight
Typical move
8.5%
average across 2 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
COMP360 psilocybin
Phase 2 · PTSD - Post Traumatic Stress Disorder

Full Press Release Details

Compass Management will host a conference call at 8:00 am ET (1:00 pm UK)

LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS#Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the second quarter and first half ended June 30, 2026, on August 5, 2026.
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on August 5, 2026. A live webcast of the call will be available on the Compass Pathways website at:https://events.q4inc.com/attendee/246696001. The webcast will be archived for 30 days.

About Compass Pathways

We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. We are leading the world’s largest classic psychedelic clinical program in TRD, and building upon that robust foundation, we are executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing.
Compass is headquartered in London, UK, with a U.S. office in New Jersey.
We are driven by our purpose of unlocking pathways to be – opening futures filled with possibility. Together, we are on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery, because every journey needs a Compass.

Enquiries

Media: Dana Sultan-Rothman,media@compasspathways.com
Investors: Stephen Schultz,stephen.schultz@compasspathways.com, +1 401 290 7324

Frequently Asked Questions

When will Compass Pathways announce its financial results?

Compass Pathways will announce its financial results on August 5, 2026.

What time is the conference call for financial results?

The conference call will be held at 8:00 am ET on August 5, 2026.

Where can I watch the conference call?

The conference call will be available via a live webcast on the Compass Pathways website.

What period do the financial results cover?

The financial results cover the second quarter and first half ended June 30, 2026.

Last updated: Jul 29, 2026